{"disease":{"id":"mrd","name":"mrd"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT03971305","title":"A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07254156","title":"A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":229,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05536505","title":"Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Guangdong Association of Clinical Trials","has_results":false},{"nct_id":"NCT04010968","title":"Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT07120698","title":"Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Guangdong Association of Clinical Trials","has_results":false},{"nct_id":"NCT04126967","title":"Next Generation Sequencing（NGS）Monitors Minimal Residual Disease（MRD）in Allo-PBSCT Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Xianmin Song, MD","has_results":false},{"nct_id":"NCT07264010","title":"Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":87,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT07441291","title":"CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07371247","title":"Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy","phase":"EARLY_PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":65,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05441566","title":"Significance of MRD After Surgery in Driver Gene-positive and Driver Gene-negative Stage IB-IIA NSCLC","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":60,"lead_sponsor_name":"Shenzhen People's Hospital","has_results":false},{"nct_id":"NCT06409702","title":"Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":59,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05736978","title":"Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"Shanghai Tong Ren Hospital","has_results":false},{"nct_id":"NCT07112612","title":"Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Anhui Medical University","has_results":false},{"nct_id":"NCT05940961","title":"Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Sheng-Li Xue, MD","has_results":false},{"nct_id":"NCT06207799","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06918262","title":"Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT07013851","title":"Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Grupo Español de Investigación en Cáncer de Ovario","has_results":false},{"nct_id":"NCT06477991","title":"The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial.","phase":"","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"Yunnan Cancer Hospital","has_results":false},{"nct_id":"NCT03919526","title":"Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT07006012","title":"RGL-305+ Lymphoma + Exploratory Clinical Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT02992964","title":"Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"The Hospital for Sick Children","has_results":false},{"nct_id":"NCT04827745","title":"Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT07475923","title":"Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}